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ß-amyloid (Aß1−42) is produced by proteolytic cleavage of the transmembrane
type-1 protein, amyloid precursor protein. Under pathological conditions,
Aß1−42self-aggregates into oligomers, which cause synaptic dysfunction and neuronal
loss, and are considered the culprit of Alzheimer’s disease (AD). However, Aß1−42 is
mainly monomeric at physiological concentrations, and the precise role of monomeric
Aß1−42 in neuronal function is largely unknown. We report that the monomer of
Aß1−42 activates type-1 insulin-like growth factor receptors and enhances glucose
uptake in neurons and peripheral cells by promoting the translocation of the
Glut3 glucose transporter from the cytosol to the plasma membrane. In neurons,
activity-dependent glucose uptake was blunted after blocking endogenous Aß
production, and re-established in the presence of cerebrospinal fluid Aß. APP-null
neurons failed to enhance depolarization-stimulated glucose uptake unless exogenous
monomeric Aß1−42 was added. These data suggest that Aß1−42 monomers were
critical for maintaining neuronal glucose homeostasis. Accordingly, exogenous Aß1−42
monomers were able to rescue the low levels of glucose consumption observed in brain
slices from AD mutant mice.
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Introduction
Sporadic age-related form of AD is the most frequent yet incurable type of dementia. Difficulties in
advancing disease understanding and clinical interventions partly depend on complex interactions
between disease determinants, namely the toxic ß-amyloid1−42 (Aß1−42) species (Selkoe, 2011),
and age-related risk factors, including the decline of insulin-like growth factor 1 (IGF-1) functions
(Piriz et al., 2011), and the occurrence of peripheral insulin resistance or diabetes (Jayaraman
and Pike, 2014). These intervening factors, among others, might progressively overcome the
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ability of the brain cognitive reserve to buffer the impact of
the pathology on cognitive functions. Specifically, Stranahm and
Mattson have hypothesized that the cognitive reserve relies on
insulin/neurotrophic factor signaling and glucose metabolism
that all set the brainmetabolic efficiency (Stranahan andMattson,
2012). The AD brain shows impairments of insulin/IGF-1
signaling (de la Monte, 2012) and glucose metabolism (Caselli
et al., 2008), which only in some cases depend on a comorbid
systemic disease (de laMonte, 2012), and are largely unexplained.
Talbot et al. (2012) have provided direct evidence that AD
brain tissue is insulin resistant in the absence of diabetes, and
that histological biomarkers of insulin resistance co-localize
with Aß plaques. Interestingly, in the same study, they found
a strong resistance of type-1 IGF receptor (IGF-IR) to ligand
activation even in brain regions where amyloid plaques are found
in a very late stage of AD (Talbot et al., 2012). It remains
unknown whether and how this last finding is relevant to the
pathophysiology of AD and is related to the low rate of brain
glucose metabolism that starts decades before the clinical onset
of dementia (Reiman et al., 2004; Mosconi et al., 2006; Caselli
et al., 2008). Here we provide evidence that, both in native
and recombinant systems, IGF-IRs can be activated by the
monomer of Aß1−42, the predominant form of the protein at
physiological concentrations (Nag et al., 2011). In recombinant
cells, monomeric Aß1−42 acts as a positive allosteric modulator
of IGF-IRs endowed with a small intrinsic efficacy, thereby
enhancing IGF-1 effects. Through IGF-IR activation, Aß1−42
monomers control glucose uptake in neurons under both basal
and depolarizing conditions. Interestingly, Aß1−42 monomers
rescue the low levels of glucose consumption observed in brain
slices from AD transgenic mice, which are resistant to IGF-
1 stimulation. We suggest that a defective IGF-IR signaling
contributes to AD progression via a disease-specific mechanism
involving the loss of receptor activation by Aß monomers, which
become depleted when pathological aggregates are formed.
Materials and Methods
Synthesis of Pentapeptides
Pentapeptides (KLVFF, VFLKF, klvff, ffvlk) were synthesized
by means of microwave-assisted solid phase peptide synthesis
on a CEM “Liberty” peptide synthesizer using standard 9-
fluorenylmethoxycarbonyl (Fmoc) chemistry. Peptides were
cleaved off from the solid support using a mixture of
Trifluoro-acetic acid (TFA)/water (H2O)/tri-isopropyl-silane
(TIS) 95/2.5/2.5 (v/v/v), then precipitated with cold freshly
distilled diethyl ether. Crude peptides were purified by
preparative RP-HPLC. Samples identity was confirmed by
ESI-MS (Calculated mass for C37H55N7O6: 693.42; Observed
[M+H]+: 694.58).
To control for KLVFF effects, in addition to the retroinverse
ffvlk, which maintains the overall spatial topology of KLVFF,
we chose to synthesize both the scrambled peptide, VFLKF, and
the D-enatiomer klvff. The latter is very likely to bind Aß1−42
as the parent KLVFF (Chalifour et al., 2003), thus ruling out
the possibility that KLVFF acts by stabilizing endogenous Aß
monomers.
Peptide Sample Preparation
Aß1−42 and Aß1−16 were purchased from Bachem Distribution
Services GmbH, Germany. Aß17−42 was purchased from
Innovative Peptide Solutions, Germany. All peptides were
dissolved in trifluoroacetic acid (TFA) at a concentration of
1mg/ml and sonicated for 10min. TFA was removed by gentle
streaming of argon. Peptides were then dissolved in 1,1,1,3,3,3-
hexa-fluoro-2-propanol (HFIP) and incubated at 37◦C for 1 h.
Following argon streaming, peptides were dissolved again in
HFIP, lyophilized and then resuspended in 5mM anhydrous
dimethyl sulfoxide (DMSO) prior to dilution to 100µM in ice-
cold cell culture medium DMEM-F12.
Circular Dichroism Measurements
CD spectra were recorded at 37◦C under a constant nitrogen
flow on a JASCO model J-810 spectropolarimeter, equipped with
a Peltier thermostatted cell holder. CD spectra were run in the
far-UV region (200–260 nm) using 1 cm path length cuvettes.
CD spectra were acquired every 30min over a time course of
1200min. Buffer contribution to the CD intensity was subtracted
from peptide CD spectra.
Thioflavin T (ThT) Fluorescence Measurements
Fluorescence measurements were performed on a Perkin Elmer
LS 55 spectrophotofluorimeter equipped with a thermostatic
cell holder. The experiments were carried out at 37◦C using a
1 cm light path quartz. ThT (45µM) emission fluorescence was
followed for 1200min by monitoring the increase in the dye
intensity at 480 nm, with a 440 nm excitation wavelength. The
excitation and emission slit widths were set at 5 nm.
Rayleigh Scattering Measurements
Rayleigh scattering measurements were performed on a Perkin
Elmer LS 55 spectrophotofluorimeter at 37◦C in a 1 cm path-
length cell. Peptide samples were excited at 400 nm and scattering
was monitored for 1200min at 400 nm. Both excitation and
emission slits were fixed at 5 nm.
IGF-IR and IR Phosphorylation Assay
Clones of R− cells (3T3-like mouse fibroblasts with a disrupted
IGF-IR gene), stably transfected with either the human
IGF-IR (R+) or the human IR-A cDNA (R− IR-A), were
obtained as previously described (Pandini et al., 2002). Cell
lysates from R−IR-A cells or R+ cells (40µg protein/well)
were immunocaptured in Maxisorp Break-Apart immunoplates
(Nunc) coated with antibodies MA-20 (Novus Biologicals),
which recognizes the IR α-subunit, and αIR-3 (Calbiochem),
which recognizes the IGF-IR α-subunit, at a concentration of
2 and 1µg/ml, respectively, in 50mm sodium bicarbonate (pH
9.0) overnight at 4◦C. After washing, the immunocaptured
receptors were incubated with increasing concentrations of either
porcin insulin (Sigma-Aldrich) or recombinant human IGF-1
(PeproTech) (in 50mmHEPES-buffered saline (pH 7.6), 150mm
NaCl, 0.1% TritonX 100, BSA 0.05%, containing 10µM ATP,
10mM MgCl2 and 2mM MnCl2) in the presence or absence
of mAß1−42.After 2 h at RT, the plates were washed and the
captured phosphorylated proteins were incubated with biotin-
conjugated anti-phosphotyrosine antibody 4G10 (0.3µg/ml in
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50mm HEPES (pH 7.6), 150mm NaCl, 0.05% Tween 20, 1%
BSA, 2mm sodium orthovanadate, 1mg/ml bacitracin) for 2 h
at RT and then with peroxidase-conjugated streptavidin. The
peroxidase activity was determined colorimetrically by using the
TMB microwell peroxidase substrate system (KPL). The reaction
was stopped by the addition of 1.0m H3PO4, and the absorbance
was measured at 450 nm.
Neuronal Cultures: Preparation and Treatments
Animal care and experimentation was in accordance with
institutional guidelines. Cultures of pure cortical neurons were
obtained from rats at embryonic day 15 as described previously
(Giuffrida et al., 2009). Cultures of mixed cortical cells, contaning
both neurons and glia, were obtained from rats at embryonic
day 17 and grown onto poly-D-lysine coated 16mm multiwell
vessels (4 × 105 cells/well) as described previously (Giuffrida
et al., 2009). Mature cultures, at 14–16 days in vitro (DIV), were
used for the study. All experiments were performed always after
extensive washing of the cultures to avoid any interference with
serum IGF-1/IGFBP3/ALS ternary complexes.
Mature pure neuronal cultures at 7DIV were deprived
from insulin and, where required, peptide monomers were
added and maintained for 48 h. AG1024 (100 nM) and PPP
(500 nM) were applied for 30min before insulin deprivation.
Neuronal survival was assessed by 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyl tetrazolium bromide (MTT) reduction assay.
Mixed cortical cultures at maturation were exposed to 300µM
NMDA for 10min at room temperature in a HEPES-buffered
salt solution. Neuronal toxicity was examined 24 h later by light
microscopy and quantified after staining with trypan blue (0.4%
for 5min). Stained neurons were counted from three-random
fields/well. Peptide monomers were added in combination with
NMDA. Where required, AG1024 (100 nM) and PPP (500 nM)
were applied 15min before the excitotoxic pulse.
IGF-1 release in neuronal cultures was assessed by the IGFBP-
blocked IGF-1 ELISA (ALPCO Diagnostics). Cultures were
exposed to the washing protocol utilized for all the experiments
and IGF-1 content was quantitated in the culture buffer within
2 h. Low levels of IGF-1 were generally found under these
conditions (about 0.003 nM). However, IGF-1 levels strictly
depended on the experimental condition. For example, a brief
NMDA pulse lead to a 5 fold increase in the release (up to
0.017 nM). Since the assay detected total IGF-1 (free and IGFBP-
bound), measurements could not provide indications about the
active quote of the factor.
Cultures of APP-null neurons were obtained as in Giuffrida
et al. (2009) except that cortices from newborn mice (within
12 h from birth) were used. Homozygous APP-null male and
female mice (B6.129S7-Apptm1Dbo/J) on a C57BL/6J genetic
background were purchased from Charles River, and the colony
has been established in the animal house of the University of
Catania.
Imaging of 6-NBDG Up-take in Neurons by Laser
Scanning Confocal Microscopy (LSM)
Neurons were plated on glass bottom culture dishes and were
used at 6–8DIV. For the experiments, cultures were rinsed
with glucose-free HCSS (120mmol/l NaCl, 5.4mmol/l KCl,
1.8mmol/l CaCl2, 20mmol/l HEPES pH 7.4) and kept for 45min
under glucose deprivation followed by exposure for 30min to
either mAß1−42 (100 nM), or recombinant rat IGF-1 (5 ng/ml,
R&D Systems). The non-hydrolyzable glucose analog 6-NBDG
was allowed to be internalized into neuronal cells at 37◦C
and 5% CO2 for 10min. 6-NBDG
+ neurons were imaged by
using an Olympus FV1000 LSM. Images were captured at 488
excitation/505-550 emission.
Assessment of 6-NBDG Uptake in Neurons by
Cytofluorimetric Analysis
Neurons were grown onto 35mm dishes and the experiments
were performed at 7DIV. Cultures were rinsed in glucose-free
HCSS and maintained for 45min under glucose deprivation
followed by exposure to either mAß1−42 (100 nM) or IGF-
1 (5 ng/ml) for 30min, or to KCl (40mM) for 15min. PPP
(500 nM) was added 15min before mAß1−42 . When required, a
γ-secretase inhibitor (γ-sec-Inhibitor IX, Calbiochem, 100 nM)
was added 2 h before glucose deprivation and maintained
troughout the experiment. 6-NBDG (100µM) was added 10min
before ending the experiment by rinsing the cells twice with
ice-cold phosphate buffered saline (PBS). Neurons were scraped
into ice-cold PBS and maintained at 4◦C for the cytofluorimetric
analysis (cytomics FC500, Beckman Coulter). 20,000 Events for
experimental condition (each in triplicate) were collected.
Assessment of Glucose Uptake in Neurons
Exposed to Human CSF
Neurons were grown into 96 well plates and the experiments
were performed at 7DIV. Before the experiment, glucose
concentration was measured in all CSF samples by glucose
meter, and glucose levels were therefore adjusted to the highest
measured value. For the experiment, cultures were rinsed in
glucose-free artificial CSF (124mM NaCl, 2.5mM KCl, 2mM
MgSO4, 1.25mM KH2PO4, 26mM NaHCO3, 2.5mM CaCl2)
and maintained for 45min under glucose deprivation. γ-
Sec-inhibitor IX (Calbiochem, 100 nM) was added 2 h before
glucose deprivation and maintained troughout the experiment.
Following deprivation, cultures were shifted into 50µl CSF/well
and preliminary experiments were carried out to assess neuronal
viability. Under this condition, a fast excitotoxic event occurred
and thereafter all experiments were carried out in the presence of
the NMDA receptor antagonist, MK-801 (1µM). Cultures were
maintained in CSF with MK-801 for 40min, during which no
glucose uptake occurred.
Parallel experiments carried out in artificial CSF showed that
glucose uptake in response to KCl, at the usual concentration
of 40mM, was blunted by the presence of MK-801 (glucose
consumption (mg/dl): 52.75± 1.5 and 47.27± 1.6–basal vs. KCl,
respectively). However, a relevant glucose uptake was observed
by rising KCl concentration to 400mM (glucose consumption
(mg/dl): 53.25± 2.8 and 38± 2.3–basal vs. KCl, respectively).
Neurons were therefore maintained in CSF + MK-801 for
40min, then glucose consumption was measured in a 5µl
aliquot by glucose meter before adding 400mM KCl for 15min.
Measurements of glucose consumption were taken again at the
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end of the pulse, and glucose uptake was calculated with respect
to the initial values.
L6 Cell Cultures
L6 rat skeletal muscle cells (EACC) were cultured in 5% CO2 in
DMEM (Invitrogen) supplemented with 10% fetal bovine serum
(FBS) and 1% penicillin/streptomycin. Once the cells reached
80% confluence, they were split (using 0.25% trypsin-EDTA) into
fractions and propagated or seeded to be used in the experiments.
To induce differentiation into the myotubes that were used for
experiments, cells were made confluent and the concentration
of FBS was then reduced to 1% for 24–48 h. Cells were passaged
biweekly. Passages 10–30 were used for all the experiments.
Measurement of 6-NBDG Uptake in L6 Cells
L6 myotubes, seeded in 22mm glass bottom dishes, were placed
in Krebs’Ringer buffer (136mM NaCl, 20mM HEPES, 2mM
NaHCO3, 0.5mM NaH2PO4, 3.6mM KCl, 0.5mM MgCl2, and
1.25mM CaCl2, pH 7.4) without glucose for 45min. When
required, inhibitors were added for 30min during the glucose
starvation time. The stimulation of glucose uptake was obtained
by incubating cells for 15 more min with either IGF-1, mAß1−42,
or KVLFF. Cells were then loaded with 100µM 6-NBDG for
15min. The concentration and incubation time were chosen
as the best for giving an adequate signal/noise ratio. After the
loading period, culture dishes were washed twice and placed on
the stage of a FV1000 LSC microscope. Cultures were excited
at 488 nm, and 6-NBDG was imaged at 505–550 nm emission
wavelength.
Indirect Glut3 Immunofluorescence Analysis
To mimic the experimental conditions under which glucose
uptake was observed, cells seeded in round coverslips (pure
cortical neurons or L6 myotubes) were washed repeatedly and
glucose starved for 30min. When required, PPP was added
during the glucose starvation time. Cells were then washed again
and stimulated for 10min with monomeric Aß1−42 (100 nM),
KCl (40mM), or KLVFF monomers (100 nM) in the presence
of glucose. Cells were then fixed in 2% formaldehyde and
permeabilized using 0.1% Triton X-100. Unspecific binding
was blocked by 30min of incubation in 4% bovine serum
albumin (BSA) in 0.1% Triton X-100-PBS. Glut-3 was detected
by incubating over-night cells with rabbit anti-Glut-3 antibody
(1:100, Abcam). Counterstaining was obtained by over-night
incubation with mouse anti-actin (1:200, Sigma-Aldrich). After
PBS washing, cells were exposed for 1 h at RT to the respective
secondary antibody (anti-rabbit AlexaFluor 546 or anti-mouse
AlexaFluor 680). Coverslips were mounted with the ProLong
Gold antifade mounting medium (Invitrogen) and examined
under a FV1000 LSC microscope using the Fluoview Olympus
image software.
Imaging was carried out using a 63 Plan-Apo/1.4-NA
oil-immersion objective. Standard 3 confocal channel (3
photomultiplier detectors) acquisitions were made by using
the following lasers, mounted on a laser combiner: Multi-line
Argon laser (457, 488, 515 nm), total 30mW HeNe-Green laser
(543 nm), 1.5mW HeNe-Red laser (633 nm), 10mW. Single or
multiple optical sections (0.42µm z axis) through the middle
of the cells were acquired for each field. The pinhole was
adjusted to keep the same size of z-optical sections for all the
analysis. Sequential mode imaging was performed to ensure that
there was no crosstalk between the channels. Ten random fields
for each treatment were imaged, with each treatment repeated
twice in three separate experiments. Quantitative analysis was
carried out using the FV1000 single particle analysis software
(release 2). Glut3 signal spread was calculated as follows: for each
microscopic field a z-stack series, made up of 20 slices (0.42µM
thickness each), was acquired. Then, the difference between the
average fluorescence intensity/pixel, measured as z-projection in
the z-stack series, and the average fluorescence intensity/pixel,
measured for a single slice corresponding to the middle of the
neuron, was calculated.
Detection of the Glut3 Exofacial Domain
Specific detection of the N-terminal extracellular domain of
Glut3 was achieved by indirect immunofluorescence of non-
permeabilized neurons, using a goat antibody raised against a
peptide mapping within this region (1:25, Santa Cruz). Glut3
immunoreactivity was revealed with the donkey anti-goat IgG-
Texas Red, Santa Cruz). Quantitative analysis was carried out
by flow cytometry. Briefly, at the end of each treatment,
neurons were harvested, washed once with PBS and pelleted.
The cell pellet was fixed by incubation with 200µl of 2%
formaldehyde for 1 h at RT. Fixed cells were blocked with 4%
BSA, and stained by 2 h incubation at RT with the exofacial
Glut3 antibody. Stained cells were then washed twice, and
finally revealed by 1 h incubation with the secondary Texas Red-
conjugated antibody. Immunostained samples were checked by
cytofluorimetric analysis with a CyFlow R© ML flow cytometer
system (Partec). Neurons were excited by an air-cooled argon
488 nm laser and Texas Red signal was read on FL3 detector.
The data acquired (20,000 cells per sample) were compensated,
gated and analyzed using FlowMax software (Partec). Each
experimental condition was repeated in triplicate.
Western Blotting Analysis
Western blotting analysis for phospho-eIF-4E binding protein
(p4EBP1) or phospho-IGF-IR was performed on total protein
extracts (50µg) from differentiated L6 cells treated with IGF-1
(2 ng/ml), mAß1−42 (100 nM), or KLVFF (100 nM) for 15min.
Samples were loaded onto 4-12% bis-Tris Glycine gel (NuPAGE,
Invitrogen). After separation, proteins were transferred onto
a nitrocellulose membrane (Hybond ECL, Amersham Italia)
using a transblot semi-dry transfer cell. Membranes were blotted
at 4◦C o.n. with the following primary antibodies: rabbit
anti-p4EBP1 (1:1000, Cell Signaling), rabbit-anti(Y1161)IGF-IR
(1:700, Abcam), and mouse anti-ß-actin (1:1000, Sigma Aldrich).
Secondary goat anti-rabbit labeled with IRDye 680 (1:14.000
Li-COR Biosciences) and goat anti-mouse labeled with IRDye
800 (1:12.000 Li-COR Biosciences) were used at RT for 45min.
Hybridization signals were detected with the Odyssey Infrared
Imaging System (LI-COR Biosciences).
For the analysis of phospho-IRs, cell lysates were obtained
from pure neuronal cultures following a 15min stimulation.
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Cell lysates (150µg) were incubated for 2 h at 4◦C on a
rotating device with 20µl of the agarose conjugated anti-
IR β (500µg/0.25ml agarose, Santa Cruz Biotechnology).
Immunoprecipitates were pelleted, washed and resuspended
in 25µl of 1x electrophoresis sample buffer containing
dithiothreitol. Following SDS-PAGE and transfer, blots were
probed with a monoclonal anti-phosphotyrosine antibody
(1:1000, 4G10 from Merck Millipore). To search for specific
hybridization signals, membranes were incubated with a
horseradish peroxidase-conjugated secondary antibody, followed
by the SuperSignal chemiluminescent detection system. After
probing with the anti-phosphotyrosine antibody, blots were
stripped for 15min with Strip Ablot (EuroClone), and re-probed
with anti-IR β (1:1000, Cell Signaling) to control for loading.
Western blotting analysis of phospho-IGF-IR in cultured
neurons was performed on 40µg of total proteins. Membranes
were incubated over night at 4◦C with the following primary
antibodies: rabbit anti-p(Y1161)IGF-IR (1:700, Abcam), and
mouse anti-ß-actin (1:1000, Sigma Aldrich). For the detection of
hybridization signals, membranes were incubated with secondary
goat anti-rabbit labeled with IRDye 680 (1:14.000 Li-COR
Biosciences) and goat anti-mouse labeled with IRDye 800
(1:12.000 Li-COR Biosciences) for 45min at RT. Signals were
detected with the Odyssey Infrared Imaging System (LI-COR
Biosciences). Alternatively, immunoprecipitation was carried out
on neuronal lysates (150µg) by using the rabbit anti-IGF-IR β
(10µg/mg protein lysate, Cell Signaling Technology).
Quantitative Determination of Aß1−42 in Neuronal
Culture Supernatants
To mimic the experimental conditions under which 6-NBDG
was observed, neuronal cultures were rinsed in glucose-free
HCSS and maintained for 30min under glucose deprivation. KCl
(40mM) was added 15min before ending the experiment. When
required, γ-sec-Inhibitor IX (100 nM) was added 2 h before
glucose deprivation. Aß1−42 was quantitated in the collected
HCSS by using the Wako human/rat Aß42 ELISA kit, high-
sensitive. This kit detects human/rat Aßx−42 in the 0.1–20 pmol/L
range, with a sensitivity of 0.024 pmol/L; 100µl of undiluted cell
supernatants from equivalent cultures were used for the assay.
Assessment of Insulin Release in Pancreatic INS-1E
Cells
Rat INS-1E ß-cells were maintained in RPMI-1640 medium
with 11.1mmol/l D-glucose, supplemented with 10% FBS,
100U/ml penicillin, 100µg/ml streptomycin, 10 nmol/l HEPES,
2 nmol/l L-glutamine, 1 nmol/l sodium pyruvate and 50µmol/l
β-mercaptoethanol. Cells were grown in T-75 flask at 37◦c and
5% CO2and passaged every 5 days by using 0.05% trypsin-
EDTA. For the experiments, cells were plated onto 24-well
plates at a density of 0.5 × 106 cells/well and grown to
100% confluence. 18 h Before the experiment, growing medium
was replaced with fresh medium containing 5mmol/l glucose.
Insulin secretion assay was performed in HEPES balanced salt
solution (HBSS) (114mmol/l NaCl, 4.7mmol/l KCl, 1.2mmol/l
KH2PO4,1.16mmol/l MgSO4,20mmol/l HEPES, 2.5mmol/l
CaCl2, 25.5mmol/l NaHCO3, 0.2% bovine serum albumin), pH
7.2. Cells were washed andmaintained in 3mM glucose HBSS for
2 h before the switch in 15mM glucose either in the absence or in
the presence of mAß1−42 (100 nM) and KLVFF (100 nM). When
required, PPP (500 nM) was added 15min before the switch. The
supernatant was collected 15min after switching, and the total
insulin content was determined by the use of rat/mouse Insulin
Enzyme Linked Immunosorbent Assay (ELISA) kit (Millipore).
Intra-peritoneal Glucose Tolerance Test (GTT)
CD1 male mice (33-35 g body weight), C57BL/6J male mice
(8 weeks of age), and transgenic B6.129S7-Apptm1Dbo/J male
mice (APP-null, 8 weeks of age) were housed up to five for
cage and fasted for 16 h prior to the test. For the GTT, a
solution of glucose (20% in 0.9% NaCl) was administered by
intra-peritoneal (i.p.) injection (100µl/10 g body weight) and
blood glucose was measured at different time points during the
following 4 h. Blood glucose was obtained from the paw and
measured by using the blood glucose meter One Touch Vita, J&J.
Assuming a plasma volume of 1.5ml/mouse, stock solution of
Aß1−42 monomers, Ac-KLVFF-NH2 monomers or recombinant
rat IGF-1 were prepared freshly in saline so to reach the plasma
concentrations of 100 nM for monomers, and 2 ng/ml for IGF-
1. After basal blood glucose measurements, where appropriate,
monomers and IGF-1 were i.p. injected 5min before or 15min
after glucose loading. Animal care and experimentation was in
accordance with institutional guidelines.
Ex-vivo Brain Stimulation
Heterozygous TgCRND8 male mice on a 129/SVE genetic
background were initially obtained from the Center for Research
in Neurodegenerative Diseases, University of Toronto, Ontario,
Canada. The colony has been established in the Animal
House of the University of Catania, Italy. Animal care and
experimentation was in accordance with institutional guidelines.
Female TgCRND8 and non-Tg littermate mice at 12 months or
8 weeks of age were used for the experiment. Mice were sacrified
by CO2 asphyxiation, brains were removed and forebrains
were sliced with a McIlwain tissue chopper. Slices were washed
three times (for a total time of 30min) with oxygenated Krebs-
Ringer (K-R) solution (118mM NaCl, 25mM Hepes, 4.8mM
KCl, 1.3mM CaCl2, 1.2mM KH2PO4, 1.2mM MgSO4; 25mM
NaHCO3; 10mM glucose), and 300µl of the slice suspension was
diluted in single tubes in a total K-R volume of 700µl. Incubation
was carried out at 37◦C for 1 h in an aerated (95% O2,5% CO2)
water bath. Stimulation was performed with either 1 nM IGF-
1 or 100 nM Aß1−42 monomers and terminated by adding
2ml of ice-cold K-R. Slices were collected by centrifugation,
lysed, and processed for immunoprecipitation as described
elsewhere. Protein concentration of the lysates was determined
by the Bradford method before immunoprecipitation. Glucose
consumption was assessed at the beginning and at the end of
the stimulation and calculated as glucose consumption/mg of
protein.
Statistics
Data were tabulated and analyzed using SigmaPlot 12.5
statistical software. Data were analyzed for determining normal
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distribution with Shapiro-Wilk test. Mean comparison was
performed with one-way Anova or unpaired Student’s t-test.
Statistical significance level was always set to p < 0.05.
Study Approval
For animal studies, all procedures were approved by the IACUC
of the University of Catania. The use of patients’ clinical data and
CSF samples was approved by the Ethics Committee of Azienda
Ospedaliera Universitaria (AOU) Careggi of Florence.
Results
Aß1−42 Monomers Interact with, and Activate,
Type-I IGF Receptors (IGF-IRs)
We previously showed that monomeric human Aß1−42 protects
cultured cortical neurons against excitotoxic death and death
by trophic deprivation. Neuroprotection was abrogated by
inhibitors of insulin/ IGF-1 receptor signaling (Giuffrida et al.,
2009). Here, we found that neuroprotection was also produced
by rat/mouse Aß1−42 (Figures 1A,B), which is resistant to
oligomerization (Shivers et al., 1998). It was reasonable to
hypothesize that the specific amino acid sequence engaged in
the aggregation process could be required for neuroprotection.
The 16–20 amino acid sequence of Aß1−42 (KLVFF) is
critically involved in Aß1−42 oligomerization and is used as
template for the design of beta-sheet breakers (Tjemberg,
1996). Synthetic Ac-KLVFF-NH2 maintained into a monomeric
form (Supplemental Figure 1A) shared the protective activity
of monomeric Aß1−42,and its action was prevented by the
insulin/IGF-1 receptor inhibitor, AG1024, or by the selective
type-1 IGF receptor (IGF-IR) inhibitor, PPP (Figures 1A,B).
Neither the D-isomer, klvff (Supplemental Figure 1B), nor the
scrambled peptide, VFLKF (Supplemental Figure 1D), induced
neuroprotection. In contrast, the retroinverse ffvlk peptide
(Supplemental Figure 1C), which maintains the overall spatial
topology of KLVFF, was protective, albeit to a lesser extent. The
human Aß1−16 and the Aß17−42 fragments were also tested.
Monomers of Aß1−16 , a fragment that is produced by combined
α- and β- secretase activities (Nutu et al., 2013), were inactive
(Figures 1A,B). The α secretase-generated Aß17−42, which
is found in diffuse amyloid deposits and dystrophic neuritis
associated with AD plaques (Higgins et al., 1996), could not
be maintained in the monomeric conformation and rapidly
precipitated into large aggregates (Supplemental Figure 1E). This
was consistent with previous evidence showing that N-terminal
deletions enhance peptide aggregation with respect to full-length
Aß1−42 (Pike et al., 1995).
Based on neuroprotection data, we hypothesized that
monomeric human Aß1−42 could interact with insulin/IGF-1
receptors via the 16–20 KLVFF sequence. Consistent with
previous evidence (Zhao et al., 2008), a basal tyrosine-
phosphorylation of the immunoprecipitated insulin receptor
(IR) β subunit, which reflects the activated receptor, was virtually
undetectable in cultured cortical neurons both in the absence
and presence of either monomeric human Aß1−42 or Ac-KLVFF-
NH2 monomers (Figure 1C). Because of the lack of detectable
IR β phosphorylation, we could use an antibody directed against
a phosphorylated tyrosine residue common to IGF-IR β and
IR β [anti-p(Y1161) IGF-IR/p(Y1185) IR] to assess IGF-IR β
phosphorylation without the need of immunoprecipitation.
Both Aß and KLVFF monomers increased IGF-IR p(Y1161)
levels. This increase was no longer visible in the presence of
the receptor antagonist, AG1024 (Figures 1D,E). We searched
for a direct peptide-receptor interaction using 3T3-like mouse
fibroblasts with a disrupted IGF-IR gene and transfected with
either human IGF-IR (R+ cells) or type-A IR (IR-A) (R−IR-A
cells) cDNA (Pandini et al., 2002). On immunoadsorbed IGF-IRs
derived from R+ cells, monomers of Aß1−42 or Ac-KLVFF-NH2
potentiated the ability of IGF-1 to promote autophosphorylation
of the receptor-kinase domain (Figures 1F,G), with Aß1−42 also
stimulating IGF-IR autophosphorylation in the absence of IGF-1
(Figure 1F). In contrast, Aß1−42 monomers had no effect on
immunoadsorbed IR-A, both in the absence and presence of
insulin (Figure 1H).
Aß1−42 Monomers Stimulate Glucose Uptake in
Neurons by Activating IGF-IRs
IGF-1 is known to stimulate glucose uptake in neurons by
mechanism(s) similar to those used by insulin in the periphery,
including membrane translocation of glucose transporters
(Gluts) (Bondy and Cheng, 2004). We deprived cultured
neurons from glucose for 75min prior to incubations with
the fluorescent non-hydrolyzable glucose analog, 6-(N-(7-
nitrobenzen-2-oxa-1,3-diazol-4-yl)amino)-6-deoxyglucose (6-
NBDG) (Figure 2A). During starvation, neurons were exposed
for 30min to recombinant rat IGF-1 at concentrations (5 ng/ml)
that selectively activate IGF-IR and are in the physiological range
of concentrations in the CSF (Bilic et al., 2006). This treatment
caused a significant increase in 6-NBDG uptake, as assessed by
confocal microscopy or flow-cytometry (Figures 2B,E). Flow-
cytometry showed a single cell population (Figure 2D) from
which 6-NBDG+ neurons were scored. Consistent with its ability
to engage IGF-IRs, monomeric Aß1−42 (100 nM) increased
the population of 6-NBDG+ neurons following starvation,
and its action was prevented by the IGF-IR inhibitor, PPP
(Figures 2C,E). Thus, Aß1−42 monomers displayed IGF-1-like
metabolic activity in cultured neurons. This, combined with the
evidence that Aß1−42 is released from neurons in response to
synaptic activity (Cirrito et al., 2005), provided the hint for testing
the hypothesis that Aß1−42 monomers might function to increase
glucose uptake during neuronal activation. A depolarization
pulse with KCl (40mM for 15min) caused a significant increase
in glucose uptake, which occluded any additional effect of
Aß1−42 monomers (Figure 2F). Depolarization-induced glucose
uptake was prevented by pretreatment with PPP (500 nM for
20min), suggesting that endogenous activation of IGF-IRs was
required for activity-dependent energy supply (Figure 2F).
Addition of a γ-secretase inhibitor (γ-secretase inhibitor IX,
100 nM), which blocked the endogenous production of Aß1−42
(Figure 2G), blunted depolarization-induced glucose uptake,
which was re-established by exogenous Aß1−42 monomers
(Figure 2F). In neuronal cultures prepared from APP-null mice,
KCl-induced depolarization failed to enhance glucose uptake
unless exogenous Aß1−42 was added (Figure 2H).
To examine whether native human Aß could share this
activity, we carried out a set of experiments using CSF samples
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FIGURE 1 | Aß1−42 monomers activated IGF-IRs, but not IRs in
primary neurons and recombinant cells. The selective inhibitor of
the IR superfamily, AG1024, and the preferential IGF-IR inhibitor, PPP,
prevented the neuroprotective activity of Aß1−42 monomers, either
human (mAß) or rat/mouse (R/M mAß), and of Ac-KLVFF-NH2
monomers (KLVFF) against NMDA-induced toxicity (A) or
insulin-deprivation (B). In (A,B) values are means ± S.E.M. of eight
determinations from two independent experiments. Significantly different
from NMDA (*) or from the respective peptide condition (#) at p < 0.05
(One-Way ANOVA + Fisher’s LSD test). (C) Representative western blot
analysis of immunoprecipitated IR beta subunit (IR) in neuronal extracts
from control cultures (CTRL) or cultures exposed for 15min to 100 nM
of either monomeric Aß1−42 (mAß) or monomeric KLVFF peptide. IR
bands are shown as control for loading. (D) Representative western
blot analysis of IGF-IR p(Y1161) with the corresponding ß-actin. Data
refer to neuronal extracts from control cultures (CTRL), or cultures
exposed for 15min to 100 nM of either monomeric Aß1−42 (mAß) or
monomeric Ac-KLVFF-NH2 peptide (KLVFF) both in the presence and
absence of AG1024 (100 nM). Identical results were obtained in
experiments in which IGF-IR p(Y1161) was assessed in IGF-IR
immunoprecipitates. (E) Densitometry of three separate western blots
in which IGF-IR p(Y1161) signals were normalized either on ß-actin or
total IGF-IR. Values (means ± S.E.M., n = 2−3) are expressed as %
of the respective controls. *p < 0.05 vs. CTRL by One-Way Anova +
Fisher’s LSD test. (F) Autophosphorylation of immunocaptured human
IGF-IR in response to IGF1, mAß, or a combination of both. (G)
Autophosphorylation of immunocaptured human IGF-IR in response to
IGF1, KLVFF, or a combination of both. The lack of effects of the
scrambled peptide, Ac-VFLKF-NH2 (VFLKF), is also shown. Both in
(F,G) data are the means ± S.E.M. of three independent experiments
and are expressed as % over basal receptor phosphorylation.
*Significant at p < 0.05 vs. IGF-1 alone, or vs. basal (#) (One-Way
Anova + Fisher’s LSD test). (H) Autophosphorylation of
immunocaptured human IR-A in response to insulin (Ins), Aß1−42
monomers (mAß) or a combination of both. Data are representative of
two experiments and are expressed as % over basal receptor
phosphorylation. Phosphorylation was quantitated by ELISA as
described under Methods.
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FIGURE 2 | Aß1−42 monomers stimulated glucose uptake in neurons
by activating IGF-IRs. Confocal images of 6-NBDG uptake in live neurons
(A) exposed to either IGF-1 (5 ng/ml) (B) or monomeric Aß1−42 (mAß) (C) for
30min after starvation, scale bar = 10µm. (D) Representative scatter plot of
the neuronal population examined by flow-cytometry. Percentage of
6-NBDG+ neurons following treatments was scored by flow cytometry in
(E,F). (E) The IGF-IR antagonist, PPP, prevented neuronal 6-NBDG uptake
induced by Aß1−42 monomers (mAß). Values are means ± S.E.M. of two
independent experiments. *Significant at p < 0.05 vs. controls (CTRL), or vs.
mAß(#) (One-Way Anova + Fisher’s LSD test). (F) The IGF-IR antagonist,
PPP, and the γ-secretase inhibitor IX (γ-Sec inh) prevented neuronal 6-NBDG
uptake induced by a 15min depolarization pulse with KCl. Values are means
± S.E.M. of two independent experiments. *Significant at p < 0.05 vs.
controls (CTRL), or vs. KCl (**), or vs. γ-Sec inh + KCl (#) (One-Way Anova +
Fisher’s LSD test). (G) γ-Secretase inhibitor IX blocked the endogenous
production of Aß1−42 under both basal and depolarizing conditions. Values
are means ± S.E.M. of three determinations from one representative
experiment that was carried out under conditions similar to those utilized for
the assessment of neuronal 6-NBDG uptake. γ-Secretase inhibitor IX (γ-Sec
Inh) was present in the cultures for 2 h before washing and shifting into a
glucose-free buffer for 30min. Glucose-free buffer collected after 30min, in
the absence of γ-Sec inh., is reported as control condition. Where indicated,
KCl was added 15min before collecting the buffer. Aß1−42 was quantitated
in the collected buffer by using the Wako human/rat Aß42 ELISA kit,
high-sensitive. Significant at *p < 0.05 and at **p < 0.01 vs. control, and at
#p < 0.01 vs. KCl alone (One-Way ANOVA + Fisher’s LSD test). (H)
Percentage of 6-NBDG+ neurons in APP-null cultures and related wt
cultures. Values are means ± S.E.M. *Significant at p < 0.05 vs. respective
controls (CTRL) in the wt (n = 3− 4) and in the APP-null condition (n = 6–9)
(One-Way Anova + Holm-Sidak test).
obtained from 4 MCI and 4 AD patients (Figure 3A). CSF levels
of Aß1−42 in MCI patients (1032 ± 102 pg/ml) approximated
the reference values of healthy individuals, whereas average
levels in AD patients were about 3 fold lower (384 ± 36
pg/ml). CSF glucose contents varied among samples (Figure 3A),
and were made uniform by addition of exogenous glucose.
Cultured neurons, incubated with inhibitor IX to block the
endogenous production of Aß1−42,were starved for 45min and
then incubated with human CSF. Glucose uptake stimulated by
high K+ did not significantly differ between cultures incubated
with MCI and AD CSF, although a trend to a reduction in
AD-CSF treated cultures was seen (Figure 3B). We used the
neutralizing 4G8 monoclonal antibody, which bound Aß but not
APP in human CSF samples under non-denaturating conditions.
Native CSF samples, as immunoprecipitated by 4G8 antibody
and revealed by the G2-13 antibody, showed the 4 kD Aß1−42
monomer, but not the expected 100 kD band corresponding to
APP (Figure 3C). Addition of the 4G8 antibody (100 ng/50µl
CSF) significantly reduced glucose uptake at least in cultures
treated with MCI CSF (Figure 3B and related legend). This
indicated that native human Aß was able to support glucose
uptake in neurons.
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FIGURE 3 | Native human Aß stimulated glucose uptake in
neurons. (A) Summary of the cases used in this study. CSF samples
were from the Department of Neurological and Psychiatric Sciences,
University of Florence. Clinical diagnosis of AD was defined according
to the Diagnostic and Statistical Manual of Mental Disorders criteria
(DSM-IV). Clinical diagnosis of MCI was defined according to Petersen’s
validated criteria (Petersen et al., 2001). CSF Aß1−42 was quantitated
by INNOTEST ß-amyloid (1–42) from Innogenetics. (B) Contribution of
CSF Aß monomers to depolarization-induced neuronal glucose uptake
both in the absence (IgG2b isotype control) and in the presence (4G8)
of a neutralizing anti-Aß antibody. Neurons were pre-exposed to the
γ-secretase inhibitor IX and underwent a 15min depolarization pulse
with 400mM KCl (γ-Sec Inh + KCl). Mean values of glucose uptake
(mg/dl) after the pulse were the following: 47.75 ± 4.77 vs. 33.87 ±
4.54* (*different at p < 0.05, n = 4) in the MCI condition in the
presence of IgG2b or 4G8, respectively; 38.13 ± 6.03 vs. 27.72 ±
2.14 (n = 4) in the AD condition in the presence of IgG2b or 4G8,
respectively. Each n was run in duplicate and expressed as mean. (C)
The ß-amyloid (17–24) 4G8 monoclonal antibody does not bind APP
in human CSF samples under non-denaturing conditions. 200ml of a
MCI CSF sample, containing 1076 pg/ ml of Aß1−42, were treated
with 4G8 antibody (Covance, 100 ng/50ml) under native conditions for
2 h, before proceeding with the immunoprecipitation protocol. Western
blot analysis was then performed both in the immunoprecipitated pellet
(left) and in the supernatant (right). Three different antibodies were
used to reveal APP and/or Aß in the samples. Both the 6E10
monoclonal antibody (Covance, 1:1000 dilution) and the 12B2
monoclonal antibody (IBL International, 5mg/ml) failed to reveal the
expected 100 kD band corresponding to APP in the pellet (left), but
showed the APP band in the supernatant (right) (see arrow). Bands
smaller than 100 kD, likely corresponding to Aß aggregates, were
visible both in the supernatant and in the immunoprecipitated. An
additional antibody, the G2-13 monoclonal antibody that specifically
recognizes Aß1−42 at the C-terminus (Millipore, 1mg/ml), was sensitive
enough to detect the 4 kD Aß1−42 monomer at the electrophoresis
front of the immunoprecipitated (left) (see arrow).
Aß1−42 Monomers Promote Membrane
Translocation of Glut3 in Neurons by Activating
IGF-IRs
The membrane transporters, Glut3 and Glut4, mediate glucose
transport in neurons (McEwen and Reagan, 2004). Glut3 has a
neuropil localization (McEwen and Reagan, 2004), which might
enable glucose transport in neurons to uphold glucose uptake
during synaptic activity. Depolarization is known to promote the
fusion of Glut3 vesicles with the cell surface in neurons (Uemura
and Greenlee, 2006). In our cultures, K+-induced depolarization
increased basal Glut3 immunoreactivity (Figures 4A,B) in
neuronal threads, as well as in perikarya and axon hillocks
(Figures 4G,H). Aß1−42 monomers induced a similar pattern of
Glut3 immunoreactivity (Figures 4C,D), which was prevented
by pretreatment with PPP (Figures 4E,F). The intense Glut3
immunoreactivity profiling neuronal perikaryon was paralleled
by a reduction of Glut3 signal spread assayed in a z-
stack series of neuronal slices (Figure 4I), suggesting that
Aß1−42 monomers were promoting Glut3 translocation. Glut3
translocation was also assessed by immunolabeling neurons with
an antibody raised against the exofacial epitope of Glut3 in
the absence of membrane permeabilization. Both monomeric
Aß1−42 and Ac-KLVFF-NH2 increased immunoreactivity for
exofacial Glut3 as assessed by immunocytochemistry and
cytofluorimetric analysis (Figures 4J–P). Consistent with the
membrane translocation of Glut3, Aß1−42-induced glucose
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FIGURE 4 | Monomers of Aß1−42 and Ac-KLVFF-NH2 induced Glut3
translocation at neuronal plasma membranes. Confocal images of
neurons co-immunolabeled for Glut3 and ß-actin (A,B) following 10min
stimulation with 100 nM Aß1−42 monomers (mAß) both in the absence
(C,D) and presence of the IGF-IR antagonist, PPP (E,F), or with 40mM
KCl (G,H). Before stimulations, neurons were glucose-deprived for 30min.
Arrows point to Glut3 immunoreactivity profiling neuronal perikarya in
(C,D,G); arrowheads point to Glut3 immunoreactivity profiling neuronal
threads in (D) and (H). Scale bars indicate low magnification (A,C,E,G)
and high magnification (B,D,F,H) images. (I) Glut3 signal spread assayed
in a z-stack series of neuronal slices as described under methods. Ten
random fields for each experimental condition were imaged, and 10
neurons/field were scored. Each treatment was repeated twice in three
separate experiments. Bars represent fold decrease of signal spread
compared to controls (CTRL). *Significant at p < 0.05 vs. controls (CTRL),
or vs. mAß (#) (One-Way Anova + Fisher’s LSD test). (J,L,N) Confocal
imaging of the N-terminal extracellular domain of Glut3 in adherent
non-permeabilized neurons. Immunostaining was barely visible under
control conditions (CTRL). Arrowheads point to plasma membrane profiles
in neurons that were exposed to 100 nM of either monomeric Aß1−42
(mAß) (L) or Ac-KLVFF-NH2 monomers (KLVFF) (N) for 10min after
glucose starvation. Scale bar = 10µm. (K,M,O,P) Glut3 immunostaining
carried-out in harvested non-permeabilized neurons and quantified by flow
cytometry. Representative histograms displaying Glut3 fluorescence
intensity (FL3) on the x-axis and the numer of events (counts) on the
y-axis are shown for controls (K), mAß (M), and KLVFF (O). The
percentage of positive neurons is gated under RN1. (P) Bars represent
means ± S.E.M of three determinations. 20,000 Neurons/determination
were acquired. *Significant at p < 0.05 vs. controls (CTRL) (One-Way
Anova + Fisher’s LSD test).
uptake occurred at concentrations (1.5mM) at which only Glut3,
which has the lowest Km among all Gluts, is likely to function
(Simpson et al., 2008) [extracellular glucose (mg/dl): 32.3 ± 4.7
and 18.7 ± 2–control vs. 100 nM Aß1−42 , respectively; n = 4–5,
p = 0.0127]. This putative Glut3-dependent glucose uptake was
sensitive to the PI-3K-inhibitor, LY294002, [extracellular glucose
(mg/dl): control (30.810 ± 1.975), 100 nM Aß1−42 (17.90 ±
0.473)∗, 100 nM Aß1−42 + 10µM LY294002 (26.950 ± 3.086)
∗;
n = 4, ∗p = 0.004 compared to the respective controls by
One-Way Anova + Fishers’ LSD], consistent with our previous
demonstration that Aß1−42 monomers activate the PI-3K/AKT
pathway in neurons (Giuffrida et al., 2009).
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Difference in IGF-IR Response to Aß1−42
Monomers between AD Transgenic Mice and
Wild-type Littermates
We examined responses to IGF-1 and Aß1−42 monomers in
forebrain slices prepared from AD mutant mice and their wt
littermates. We used both 12-month old CRND8 mice, which
show severe Aß plaque burden (Hanna et al., 2012), and 8-
week old CRND8 mice, which show sporadic Aß deposits
and perform normally (Chishti et al., 2001). At 12 months of
age, physiological concentrations of exogenous IGF-1 (1 nM)
enhanced Tyr-phosphorylation of IGF-IRs in wt but not in
CRND8 slices. In contrast, exogenous monomeric Aß1−42
(100 nM) enhanced IGF-IR phosphorylation in CRND8 but not
in wt slices. Basal glucose consumption was lower in CRDN8
slices and unresponsive to IGF-1. In contrast, monomeric Aß1−42
substantially increased glucose consumption in CRND8 slices.
None of the treatments influenced glucose consumption in wt
slices (Table 1). At 8 weeks of age, the IGF-IR response to either
IGF-1 or Aß1−42 monomers was similar in forebrain slices of
CRND8 mice and wt mice, as it was basal glucose consumption
(Table 1).
Peripheral IGF-1-like Actions of Aß1−42
Monomers
To strengthen the evidence that monomeric Aß1−42 has IGF-
1-like activity, we extended the analysis to classical peripheral
actions of IGF-1. L6 rat skeletal muscle cells express both
IGF-IRs (Beguinot et al., 1985) and Glut3 (Bilan et al.,
1992). We assessed the phosphorylation state of the IGF-IR
β subunit by using the antibody directed against the specific
phosphorylated tyrosine residue, Y1161, common to the IR
β subunit. Because the density IGF-I binding sites is one-
hundred fold higher than the density of insulin binding sites
in L6 cells (Beguinot et al., 1985), we used the anti-pY1161
antibody for the assessment of IGF-IR β phosphorylation
without immunoprecipitation. In L6myotubes, IGF-1 stimulated
IGF-IR phosphorylation at concentrations as low as 2 ng/ml
(Figure 5A). Both monomeric Aß1−42 and Ac-KLVFF-NH2
behaved similarly to IGF-I (Figure 5A), and enhanced the
amount of phophorylated high-molecular weight eIF-4E binding
protein, 4E-BP1 (Figure 5A), which is a downstream target of
both the MEK/ERK and the PI-3K/AKT pathways (Kelleher and
Bear, 2008). Similar to IGF-1, Aß1−42 monomers also increased
Glut3 immunoreactivity in myotubes (Figure 5B). Monomeric
Aß1−42 and Ac-KLVFF-NH2 (both at a 100 nM) stimulated 6-
NBDG uptake as assessed by confocal microscopy (Figure 5C)
and cytofluorimetric analysis (Figure 5D). Under all treatments,
6-NBDG uptake was prevented by the MEK inhibitor, UO126,
but not by the PI-3K inhibitor, LY294002 (Figure 5E).
Physiological concentrations of IGF-1 inhibit insulin secretion
from pancreatic ß cells (Van Schravendijk et al., 1990).
Similarly to IGF-1, monomers of Aß1−42 and Ac-KLVFF-
NH2 (injected i.p. to obtain plasma concentrations of 100 nM)
caused a transient increase in blood glucose levels in CD1
mice undergoing a glucose tolerance test (GTT), which reflects
the inhibition of insulin secretion (Figure 6A). Blood glucose
levels during GTT were higher in the C57BL/6J strain than
in the CD1 strain, consistent with the evidence that C57BL/6J
mice have an inherited impaired glucose tolerance (Toye
et al., 2005). In C57BL/6J mice, monomers of Ac-KLVFF-
NH2 did not affect significantly blood glucose levels during
GTT; however, in the congenic APP-null mice undergoing GTT,
monomers of Ac-KLVFF-NH2 were able to sustain the rise in
blood glucose levels when injected 15min after glucose load
(Figure 6B).
We also used INS-1E insulinoma cells, which secrete insulin
in response to glucose (Hohmeier et al., 2000). We observed
a 1.2–2 fold increase in insulin release by shifting the cells
TABLE 1 | Difference in the forebrain response to either IGF1 or Aß1−42 monomers between CRND8 transgenic and non-transgenic littermate mice.
TgCRND8 (1 year old) Non-Tg (1 year old)
p(Y1161) IGF-IR levels Glucose consumption p(Y1161) IGF-IR levels Glucose consumption
(% of basal) (µmol)/hr (% of basal) (µmol)/hr
Basal 100 0.2 ± 0.02 100 0.35 ± 0.01
IGF1, 1 nM 88.5 ± 5.35 0.2 ± 0.018 153.467 ± 14.91* 0.35 ± 0.02
mAß, 100 nM 147.767 ± 4.68* 0.34 ± 0.014# 74.543 ± 12.25 0.35 ± 0.015
TgCRND8 (8 week old) Non-Tg (8 week old)
p(Y1161) IGF-IR levels Glucose consumption p(Y1161) IGF-IR levels Glucose consumption
(% of basal) (µmol)/hr (% of basal) (µmol)/hr
Basal 100 3.77 ± 0.322 100 3.71 ± 0.5
IGF1, 1 nM 129.333 ± 10.477** 3.42 ± 0.310 147.667 ± 9.735** 3.69 ± 0.798
mAß, 100 nM 125.333 ± 4.910** 3.03 ± 0.460 176.333 ± 7.446** 3.32 ± 0.381
Data were collected following ex-vivo stimulation of the brains, as described in the methods. p(Y1161)IGF-IR values (mean ± S.E.M., n = 3) are expressed as percentage of basal levels
following normalization of the western blot hybridization signals. Different from its own basal at *p < 0.05 or at **p < 0.001. Glucose consumption was measured in the incubation buffer
of the samples (n = 3 for 1 year old mice and n = 4 for 8 week old mice) at the beginning and at the end of the ex-vivo stimulation. #Different from basal at p < 0.05 (mean ± S.E.M.,
n = 3).
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FIGURE 5 | IGF-1-like actions of Aß1−42 monomers in L6 rat
skeletal myotubes. (A) Left side: representative western blot of
p(Y1161) IGF-IR in L6 extracts from control cultures (CTRL), or cultures
exposed for 15min to 100 nM of either monomeric Aß1−42 (mAß) or
monomeric Ac-KLVFF-NH2 peptide (KLVFF). ß-actin bands are shown as
control for loading. Bars refer to densitometric analysis of three separate
western blots. Values (means ± S.E.M., n = 3) are expressed as % of the
respective controls. *p < 0.05 vs. CTRL by One-Way Anova + Fisher’s
LSD test. Right side: representative western blot analysis of
phosphorylated 4E-BP1 (p4E-BP1) in L6 extracts from control cultures
(CTRL) or cultures exposed for 15min to 100 nM of either monomeric
Aß1−42 (mAß) or monomeric Ac-KLVFF-NH2 peptide (KLVFF). Levels of
high-molecular weight p4E-BP1 isoform (see arrow) were increased by
either mAß or KLVFF. ß-actin bands are shown as control for loading.
IGF-1 (2 g/ml) was used as a positive control within the experiments. Bars
refer to densitometric analysis of three separate western blots. Values
(means ± S.E.M., n = 3–4) are expressed as % of the respective
controls. *p < 0.05 vs. CTRL by One-Way Anova + Fisher’s LSD test. (B)
Aß1−42 monomers increased Glut3 immunoreactivity in L6 cells. Confocal
images of L6 myotubes co-immunolabeled for Glut3 and ß-actin following
15min stimulation with 100 nM Aß1−42 monomers (mAß) or 2 ng/ml IGF-1
are shown; scale bar = 140µm. (C–E) Aß1−42 monomers promoted
glucose uptake in L6 rat skeletal myotubes. Confocal images of 6-NBDG
uptake in live L6 cells exposed to either monomeric Aß1−42 (mAß) or
IGF-1 (2 ng/ml) for 15min after starvation are shown in (C); scale bar =
510µm. In (D), 6-NBDG fluorescence intensity was quantified by confocal
imaging and represented as fold change with respect to basal.
Fluorescence intensity was calculated from 300 cells/experiments in two
independent experiments. *Significant at p < 0.05 vs. basal, or vs. the
respective control condition (#) (One-Way Anova + Fisher’s LSD test). In
(E) the mean 6-NBDG fluorescence intensity of the cell population was
quantified by cytofluorimetric analysis. Bars represent means ± S.E.M of
three-four determinations. 10,000 cells/determination were acquired.
#Significant at p < 0.05 vs. the respective control condition (One-Way
Anova + Fisher’s LSD test). UO126 and LY294002 were applied during
starvation and throughout the course of the experiment.
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FIGURE 6 | Peripheral effects of Aß1−42 monomers. (A) Aß1−42
monomers transiently increased blood glucose levels in CD1 male mice
undergoing a glucose tolerance test (GTT). This effect was mimicked by the
Ac-KLVFF-NH2 peptide and by IGF-1. Fasted mice were i.p. injected with
either Aß1−42 monomers (mAß), KLVFF monomers or IGF-1 5min before
glucose loading (2 g/kg). Plots represent the fold increase of glucose levels
(Continued)
FIGURE 6 | Continued
over basal in 4 animals per experimental condition. *Significantly different from
control (CTRL) at p < 0.05 (One-Way Anova + Fisher’s LSD test). Data are
from one experiment repeated three times with similar results. (B)
Ac-KLVFF-NH2 monomers sustained the rise in blood glucose levels in
APP-null mice undergoing GTT. Mice, either C57BL/6J (WT) or APP-null, were
i.p. injected with the Ac-KLVFF-NH2 peptide 15min after glucose load.
*Significantly different from APP-null-saline at p < 0.001 (n = 4–10
animals/group, One-Way Anova + Fisher’s LSD test). (C) Aß1−42 monomers
reduced glucose-stimulated insulin release in pancreatic INS-1E cells. This
effect was mimicked by the Ac-KLVFF-NH2 peptide and was prevented by the
IGF-IR antagonist, PPP. Data, representative of three experiments, are fold
change of glucose-stimulated insulin release. Significantly different from the
15mM glucose condition (*), or the respective controls (#) at p < 0.05 and
(One-Way Anova + Fisher’s LSD test).
from low (3mM) to high (15mM) glucose concentrations.
Monomers of Aß1−42 and Ac-KLVFF-NH2 inhibited glucose-
stimulated insulin secretion, and the effect was prevented by
PPP (Figure 6C). Thus, monomeric Aß1−42 and its functional
epitope, KLVFF, exhibited IGF-1-like effects also outside the CNS.
Discussion
The amyloid hypothesis postulates that Aß1−42, in a variety of
aggregated forms, ultimately causes neurodegeneration in AD
(Selkoe, 2011). However, drugs targeting Aß1−42 burden have
been so far unsuccessful (Karran and Hardy, 2014), suggesting
the need to explore the properties of the peptide beyond
the process of aggregation. We have previously shown that
monomeric Aß1−42 has a broad neuroprotective activity, which is
sensitive to inhibitors of insulin/IGF-1 signaling (Giuffrida et al.,
2009). Here we demonstrate that the KLVFF amino acid sequence
of Aß1−42, which is recruited in the aggregation process,
retained the neuroprotective properties of full-length Aß1−42.
The additional findings that the retro-inverse pentapeptide (ffvlk)
was neuroprotective, whereas the D-pentapeptide (klvff) was
inactive, indicated a ligand-receptor interaction. IR and IGF-
IR are homologous receptors, engaging many of the same
intracellular pathways in the CNS and in the periphery (Belfiore
et al., 2009).We have found that both monomeric human Aß1−42
and KLVFF selectively stimulated Tyr-phosphorylation of native
IGF-IRs in primary cortical neurons. A direct activation of IGF-
IRs by either monomeric Aß1−42 or KLVFF was demonstrated
on immuno-captured IGF-IRs derived from recombinant cells.
Under this condition, monomers of both Aß1−42 and KLVFF
potentiated the ability of IGF-1 to promote autophosphorylation
of the receptor-kinase domain, with Aß1−42 also displaying a
low intrinsic efficacy. We concluded that monomeric Aß1−42
and KLVFF are able to interact with IGF-IRs, acting as positive
allosteric modulators, and that the KLVFF sequence of Aß1−42
is involved in this interaction. Therefore, binding of Aß1−42 to
IGF-IR may be lost when the KLVFF sequence becomes engaged
in the formation of Aß1−42 aggregates.
There is evidence that the IGF-IR is resistant to IGF-1
activation in the AD brain (Talbot et al., 2012). Why the IGF-IR
cannot be activated even by pharmacological doses of IGF-1 in
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AD brain is so far unexplained (Talbot et al., 2012). Our results
obtained in brain tissue from CRND8 mice of different ages
suggest that this could be due to the loss of Aß1−42 monomers
accompanying the course of the pathology. In forebrain slices
from old CRND8 mice with a severe Aß load, as opposed to
slices obtained from young CRND8 brains, IGF-1 was unable to
activate IGF-IRs, which, instead, remained sensitive to Aß1−42
monomers. We suggest that, by acting as an allosteric modulator,
the exogenous monomer of Aß1−42 could be able to tune IGF-IRs
in a way that cannot be accomplished by the orthosteric ligand,
namely IGF-1 (De smet et al., 2014), and this effect would be
unmasked under the condition of an advanced plaque burden
and ensuing depletion of endogenous monomers. Whether or
not the Aß1−42 monomer can activate native IGF-IR signaling
in the absence of IGF-1, thus behaving as an allosteric agonist,
remains to be established. In the brain, the endogenous tone of
IGF-1 is like to decline with age (Piriz et al., 2011) and to rise
in conjunction with pathological events (Cheng et al., 2000). The
evidence that in old non-transgenic mice (i.e., in the aged-non
injured brain), as opposed to young non-transgenic mice, Aß1−42
monomers failed to activate IGF-IRs suggests that, under our
conditions, endogenous IGF-1 could be required for the activity
of monomeric Aß1−42 .
IGF-IRs and IRs control glucose uptake in neurons as they do
in peripheral cells, i.e., by promoting membrane translocation
of specific types of glucose transporters (Bondy and Cheng,
2004; McEwen and Reagan, 2004). Glucose uptake is particularly
relevant during network activation, when activated neurons
do not rely on astrocyte-released lactate to meet their energy
demand (Ivanov et al., 2014). Neurons express Glut3, Glut4,
and Glut8; among these, Glut4 is insulin-sensitive, but it is
expressed only in few neuronal populations, whereas Glut8 never
associates with the plasma membrane (McEwen and Reagan,
2004). We found that monomeric Aß1−42 and KLVFF were
able to enhance glucose uptake in neurons via the activation
of IGF-IRs, and this action was associated with membrane
translocation of Glut3, which is localized mostly to the neuropil
(McEwen and Reagan, 2004). In agreement with the evidence
that Aß1−42 monomers activate the PI-3K/AKT pathway in
neurons (Giuffrida et al., 2009), the PI-3K-inhibitor, LY294002,
prevented glucose uptake induced by monomeric Aß1−42.
More important, we demonstrated that Aß1−42 was necessary
for activity-dependent glucose uptake in neurons. In fact, a
depolarizing pulse of K+ ions was unable to stimulate glucose
uptake if endogenous production of Aß1−42 was blunted by an
inhibitor of γ-secretase or by the genetic deletion of APP. Under
both circumstances, depolarization-induced glucose uptake was
rescued by exogenous application of monomeric Aß1−42, either
synthetic or derived from human CSF samples. Although
synthetic Aß differs from natural Aß in terms of effective
concentrations (Reed et al., 2011), our data demonstrated that
the effects of the synthetic Aß monomer were reproduced by the
endogenous rat peptide and by the human-derived peptide.
Monomeric Aß1−42 and KLVFF exhibited IGF-1-like activity
also in peripheral cells, including pancreatic β cells and
skeletal muscle cells. In both systems, as in neurons, the
endogenous tone of IGF-1 (Yang et al., 2002; Oksbjerg et al.,
2004; see also neuronal cultures in the methods section) was
likely to be relevant for the action of KLVFF, but could
be dispensable for the action of Aß1−42 monomers, which,
at least in recombinant R+ cells, displayed a small agonist
activity. In skeletal muscle cells, monomeric Aß1−42 and KLVFF
reproduced the intrinsic signaling properties of IGF-1, including
the phosphorylation of the protein synthesis regulator, 4E-BP1,
membrane translocation of Glut3, and MEK/ERK-dependent
glucose uptake. This last finding was consistent with the
evidence that, in L6 skeletal muscle cells, Glut3 depends on
the MEK/ERK pathway for membrane translocation (Taha
et al., 1997). Overall, these data strengthen the evidence that
Aß1−42 monomers were acting on IGF-IRs, suggesting a possible
contribution of monomers to the control of peripheral glucose
homeostasis.
Accordingly, due to the ability to inhibit insulin secretion,
monomers of both Aß1−42 and KLVFF raised blood glucose
levels in outbred mice injected i.p. with a glucose load. We
did not observe this effect in inbred mice with an inherited
impaired insulin release (Toye et al., 2005), unless they were
carrying a genetic deletion of APP. Hence, the condition of
constitutive glucose intolerance could determine a desensitized
response to amyloid, which was maintained instead in APP-
null mice lacking endogenous amyloid. Although these data
are a corollary of the main finding that monomeric Aß1−42
acts as a positive allosteric modulator of IGF-IRs, they point
to potentially relevant glucoregulatory properties of peripheral
amyloid deserving further investigation.
With regard to the central IGF-1-like metabolic actions of
Aß1−42 monomers, our data hint at the relevance of a loss of
Aß1−42 monomers in the pathophysiology of AD. FDG-PET
studies have shown low rates of brain glucose metabolism in
young adult at genetic risk of late-onset AD (Reiman et al., 2004),
and in presymptomatic individuals with familial AD (Mosconi
et al., 2006). FDG autoradiography in transgenic AD mice
has demonstrated a pattern of progressively reduced metabolic
activity similar to that observed in human AD (Reiman et al.,
2000). The profound resistance of the AD brain to IGF-1 (Talbot
et al., 2012), which has been replicated in AD transgenic mice
(Zhang et al., 2013 and present manuscript), could account for
the observed glucose metabolic deficits (Reiman et al., 2000;
Caselli et al., 2008). This suggestion is consistent with the
evidence that glucose metabolism in most neurons is insulin
insensitive (Lucignani et al., 1987; Talbot et al., 2012) and,
instead, regional glucose utilization parallels IGF-1 and IGF-
IR expression at least in the developing brain (Cheng et al.,
2000). We propose that the impairment of brain glucose uptake,
preceding the clinical onset of AD by years, could be due to the
early process of amyloid aggregation causing pauperization of Aß
monomers, which normally modulate IGF-IRs. Over the years,
amyloid load could progressively overcome the metabolic reserve
that supports cognitive function (Stranahan and Mattson, 2012)
leading to the onset of dementia. Finally, the evidence that brain
metabolism in AD patients is more severely impaired during
activation than at rest (Kessler et al., 1991) is consistent with the
hypothesis that the reduced neuronal secretion of Aß occurring
with aging (Cirrito et al., 2003; Tampellini et al., 2011) might
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impair the brain ability to cope with transient needs in neuronal
energy provision.
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